Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019
Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
Serum levels of vascular endothelial growth factor in lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Serum levels of angiopoietin-1, angiopoietin-2 and their receptor- Tie-2 in patients with non small cell lung cancer during chemotherapy Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Effects of chemotherapeutic drugs and TRAIL (tumor necrosis factor-related apoptosis inducing ligand) on the non-small lung cancer cells Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in lung cancer complicated with metastatic pleurisy Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001
Soluble interleukin 2 receptor ( sIL-2R ) during chemotherapy of the lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer Source: Eur Respir J 2005; 25: 329-335 Year: 2005
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009
The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Changes and significance of hepatoma-derived growth factor and vascular endothelial growth factor in serum and lung tissue from patients with lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Inhibition of proliferation of lung cancer cells by CD40 signaling through tumor necrosis factor I Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008